Compare RGNT & PRSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGNT | PRSO |
|---|---|---|
| Founded | 2004 | 2008 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6M | 13.4M |
| IPO Year | 2022 | 2000 |
| Metric | RGNT | PRSO |
|---|---|---|
| Price | $2.02 | $0.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 54.2K | ★ 256.0K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 81.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $14,573,000.00 |
| Revenue This Year | N/A | $18.48 |
| Revenue Next Year | N/A | $53.57 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5.99 |
| 52 Week Low | $1.23 | $0.58 |
| 52 Week High | $15.50 | $2.37 |
| Indicator | RGNT | PRSO |
|---|---|---|
| Relative Strength Index (RSI) | 47.93 | 40.02 |
| Support Level | $1.74 | $0.60 |
| Resistance Level | $2.27 | $0.92 |
| Average True Range (ATR) | 0.14 | 0.04 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 44.78 | 23.01 |
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.
Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices, and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz to 300 GHz. Geographically, the company generates revenue from the United States, Hong Kong, Taiwan, Europe, and the Rest of the World.